Review status
This summary is based on the full article text.
The DOI and source URL have been verified through the official Wiley article page.
The article is an empirical study published in the Journal of Management Studies. It uses longitudinal archival data from biopharmaceutical firms and tests the relationship between technology acquisitions and subsequent technology out-licensing using two-stage least squares fixed-effect regressions, robustness checks, and supplementary analyses.
Research question
How do technology acquisitions shape subsequent technology out-licensing?
More specifically, the article asks whether out-licensing functions as a post-acquisition R&D resource reconfiguration strategy, and whether this relationship depends on the uncertainty of acquired technologies and the acquiring firm’s financial slack.
Hypotheses
The article tests three hypotheses.
Hypothesis 1 proposes that technology acquisitions are associated with increased subsequent out-licensing by the acquiring firm.
Hypothesis 2 proposes that the positive association between acquisitions and subsequent out-licensing is weaker when the acquired knowledge base is more technologically uncertain.
Hypothesis 3 proposes that the positive association between acquisitions and subsequent out-licensing is weaker when the acquiring firm has higher financial slack.
Method
The study examines publicly listed biopharmaceutical firms from 1985 to 2014.
The biopharmaceutical industry is suitable for the study because firms frequently use technology acquisitions to access new R&D capabilities, and technology licensing is a common commercialization and development strategy in the sector. The industry also relies heavily on patents, which allows the authors to construct detailed measures of technological knowledge, uncertainty, and acquisition activity.
The authors built the dataset from several sources. Compustat North America was used to identify publicly listed pharmaceutical firms and collect financial data. ReCap Deloitte was used to identify technology acquisitions and licensing deals. USPTO PatentsView was used to construct patent-based measures of firms’ and targets’ technological portfolios. Pharmaprojects was used to capture product development activities.
The final dataset includes 467 unique firms and 551 technology mergers and acquisitions between 1985 and 2014. The full panel contains 5,217 firm-year observations. The main 2SLS regression models use 4,737 observations after accounting for the variables required in the estimation.
The dependent variable is technology out-licensing. It is measured as the annual count of out-licensing deals by a firm, using ReCap data. The authors use the logarithm of technology out-licensing plus one.
The first main independent variable is technology acquisitions. This is measured as the yearly count of technology acquisition deals. To ensure that the measure captures technology acquisitions, the authors count only acquisitions of target firms that had applied for patents or out-licensed technologies in the five years before being acquired.
The second acquisition-related measure is the size of the acquired knowledge base. This is measured as the cumulative number of patents associated with target firms in the five years before acquisition, aggregated at the acquirer-year level and transformed using log plus one.
Technology uncertainty is measured using the target firm’s patent backward citations. The logic is that technologies with fewer backward citations are closer to the technological frontier and therefore more uncertain. The measure is inverted so that higher values represent higher uncertainty.
Financial slack is measured as the ratio of equity to debt. The authors interpret this as potential slack that can buffer the firm from short-term resource constraints.
The study includes many controls: R&D productivity, patent stock of the acquiring firm, acquiring firm product pipeline, Phase III failures, strategic alliances, out-licensing experience, in-licensing experience, organizational myopia, industry competition, technological diversity, backward citations, R&D intensity, firm size, market growth, potential licensees, and exogenous sunk cost.
The authors use two-stage least squares fixed-effect regression to address potential endogeneity between acquisitions and out-licensing. The models include firm fixed effects, year fixed effects, and firm-clustered robust standard errors.
The instruments are changes in accounting rules from SFAS 141 and 142 and organizational capital. The first-stage test suggests the instruments are strong: the first-stage F-statistic is 74.68, above the common threshold of 10. The Hansen J-statistic is 0.944 with p = 0.331, suggesting that the overidentification test does not reject the instruments.
The authors also run robustness checks using alternative lag structures, GLM models, Poisson models, alternative measures of technology uncertainty and financial slack, and a comparison with asset divestitures as an alternative resource reconfiguration strategy.
Results / key findings
The main finding is that technology acquisitions are followed by more technology out-licensing.
In the main 2SLS second-stage model, technology acquisitions have a positive and statistically significant relationship with subsequent technology out-licensing, β = 0.117, p < 0.05. The authors interpret this as meaning that firms experience about an 11.7% increase in out-licensing for each additional technology acquisition. This supports Hypothesis 1.
The result is theoretically important because it positions out-licensing as a post-acquisition resource reconfiguration strategy. After acquiring technology-based firms, acquirers often hold more R&D opportunities than they can develop internally. Out-licensing allows them to externalize further development and commercialization while retaining ownership and strategic access to the technology.
The first moderator is technology uncertainty. The interaction between technology acquisitions and technology uncertainty is negative and statistically significant, β = -0.004, p < 0.05. This supports Hypothesis 2.
The interpretation is that firms are less likely to use out-licensing after acquisitions when the acquired technologies are harder to evaluate. If managers cannot yet assess which technologies may become valuable, they may avoid licensing them to external partners. Out-licensing uncertain technologies can create strategic risk because a firm may accidentally help a future competitor develop or commercialize a valuable technology.
Figure 1 illustrates this moderation. When acquired technology uncertainty is low, the relationship between technology acquisitions and technology out-licensing is strongly positive. When acquired technology uncertainty is high, the slope is much flatter. This means acquisitions lead to more out-licensing mainly when firms can evaluate the acquired technology base with more confidence.
The second moderator is financial slack. The interaction between technology acquisitions and financial slack is negative and statistically significant, β = -0.214, p < 0.01. This supports Hypothesis 3.
The interpretation is that firms with more financial slack have less need to use out-licensing to free resources after acquisition. They can keep more technologies in-house and continue exploring their potential internally. Firms with less slack face stronger resource constraints and are therefore more likely to use out-licensing to reconfigure their R&D portfolio.
Figure 2 shows this moderation graphically. When financial slack is low, technology acquisitions are positively associated with more out-licensing. When financial slack is high, the relationship is much weaker and can even flatten. This supports the argument that financial slack gives firms more room to keep acquired technologies inside the organization.
The combined interaction model remains consistent. When both moderators are included, the interaction between technology acquisitions and technology uncertainty remains negative and significant, β = -0.004, p < 0.05, and the interaction between technology acquisitions and financial slack remains negative and significant, β = -0.204, p < 0.05.
The authors also replicate the analysis using the size of the acquired knowledge base instead of the acquisition count. The results are broadly similar. In Table III, the size of the acquired knowledge base is positively associated with subsequent out-licensing, β = 0.120, p < 0.05. The interaction with financial slack remains negative and significant, β = -0.164, p < 0.01. The interaction with technology uncertainty is negative but weaker, with the text reporting significance at p < 0.10.
Several control variables are also informative. In the main 2SLS model, R&D intensity is positively associated with out-licensing, β = 0.003, p < 0.05. Firm size is negatively associated with out-licensing, β = -0.016, p < 0.05. Organizational myopia is negatively associated with out-licensing, β = -0.344, p < 0.05. In-licensing experience is positively associated with out-licensing, β = 0.073, p < 0.001.
The robustness checks generally support the main results. The acquisition effect remains positive and significant with a two-year lag, but becomes weaker and non-significant with a three-year lag. This suggests that technology acquisitions influence out-licensing mainly in the short to medium term after acquisition.
Alternative model specifications also support the conclusions. In the GLM model, technology acquisitions are positively associated with out-licensing, β = 0.121, p < 0.01. In the Poisson model, the acquisition effect is also positive, β = 0.257, p < 0.05. The moderation effects remain consistent: the acquisition by technology uncertainty interaction is β = -0.005, p < 0.01 in both GLM and Poisson models; the acquisition by financial slack interaction is β = -0.464, p < 0.05 in the GLM model and β = -0.458, p < 0.05 in the Poisson model.
The authors also contrast out-licensing with divestitures. Divestitures are much less frequent. In the sample, there are around 4.5 licensing deals for every divestiture. When non-R&D divestitures are excluded, there are 15.4 licensing deals for every R&D-related divestiture. This supports the idea that out-licensing is a widely used R&D reconfiguration mechanism in the biopharmaceutical industry.
The divestiture comparison also shows that out-licensing and divestiture are not identical strategies. Technology acquisitions predict more asset divestitures, β = 0.161, p < 0.05, but the moderation patterns differ. Financial slack weakens the acquisition-divestiture relationship, β = -0.176, p < 0.05, while technology uncertainty does not significantly moderate divestitures. This suggests that technology uncertainty is especially relevant for out-licensing because out-licensing involves decisions about the future use of still-owned technologies.
Overall, the evidence supports the article’s main argument: out-licensing is a distinct post-acquisition R&D resource reconfiguration strategy. It lets firms reduce internal development burden, generate revenue, preserve ownership, and benefit from licensee development efforts. However, firms are less likely to use this strategy when they cannot evaluate the acquired technologies confidently or when they have enough financial slack to develop more options internally.
Practical implications
For managers, the study shows that acquisition integration is not only about internal recombination, divestiture, or discontinuation. Out-licensing can be a strategic way to handle an enlarged R&D portfolio after technology acquisitions.
After acquisitions, firms often gain more technological opportunities than they can develop internally. Out-licensing can help managers avoid two extremes. They do not have to keep every technology inside the firm, which can overload R&D. They also do not have to abandon or divest technologies outright, which can destroy future option value. Out-licensing gives a middle path: external partners can develop the technology while the original firm retains ownership and can receive upfront fees or royalties.
The study is especially useful for R&D-intensive firms. If a firm frequently acquires technology-based companies, it should build routines for evaluating which technologies should be kept in-house, which should be licensed out, and which should be discontinued or divested.
However, the findings also warn managers not to license too quickly. When acquired technologies are highly uncertain, premature out-licensing can be risky. A technology that appears peripheral today may become strategically valuable later. If the firm licenses it too early, it may transfer development opportunities to a future competitor.
Financial slack changes the decision logic. Firms with limited slack may need to out-license because they cannot fund every R&D path internally. Firms with high slack can afford to keep more technologies in-house while they learn which projects matter most. This means that out-licensing decisions should be connected to the firm’s financial position, not only to the technological portfolio.
The article also suggests that firms with frequent technology acquisitions should consider dedicated out-licensing teams. Such teams can assess licensing opportunities, manage external partner relationships, design contracts, protect strategic technologies, and coordinate with internal R&D leaders.
For practitioners, useful diagnostic questions include:
- After a technology acquisition, which R&D assets should be developed internally?
- Which technologies are useful but not central enough to receive internal funding?
- Which technologies could be licensed out without weakening future competitive advantage?
- Is the technology mature enough to evaluate, or is uncertainty too high?
- Could out-licensing accidentally strengthen a future competitor?
- Does the firm have enough financial slack to explore more acquired technologies internally?
- Are licensing contracts designed to protect future strategic value?
- Is out-licensing being used deliberately as a portfolio reconfiguration tool, or only opportunistically?
Theoretical implications
The article contributes to research on post-acquisition resource reconfiguration by positioning technology out-licensing as a distinct reconfiguration strategy.
Prior work often emphasizes internal resource recombination, divestiture, or discontinuation after acquisitions. This article shows that out-licensing is different. It externalizes further development and commercialization while allowing the acquirer to retain ownership and potentially benefit from the technology over time.
The study also contributes to innovation management by connecting acquisitions and licensing as linked strategic transactions. Acquisitions bring external technological resources into the firm. Out-licensing can then move selected technologies outward into the market for technology. This creates a more dynamic view of open innovation, where firms both source and commercialize technologies across boundaries.
The paper contributes to resource reconfiguration theory by showing that externalization does not always mean disposal. Through out-licensing, firms can externalize recombination while retaining residual ownership and control. This adds nuance to the categories of adding, moving, deleting, divesting, and redeploying resources.
The moderation findings also sharpen theory. Technology uncertainty reduces the attractiveness of out-licensing because firms cannot confidently determine which technologies are safe to externalize. Financial slack reduces the need for out-licensing because firms can absorb more internal experimentation after acquisition.
The study also links post-acquisition integration to strategic resource constraints. When firms lack slack, out-licensing becomes more attractive because it frees financial and managerial resources. When firms have slack, they may prefer internal experimentation because they can fund more R&D options themselves.
Finally, the article contributes to licensing research by identifying technology acquisitions as an antecedent of out-licensing. This means licensing decisions are not only shaped by product-market competition, appropriability, or licensing capabilities; they can also be driven by the need to reorganize enlarged R&D portfolios after acquisitions.
Limitations
The study focuses on the biopharmaceutical industry. This is a strong context for examining technology acquisitions and licensing, but the findings may not fully generalize to industries where patents, licensing markets, and R&D pipelines work differently.
The sample includes publicly listed firms, which ensures access to financial data but may underrepresent private firms, startups, and smaller biotechnology firms that also participate heavily in technology licensing markets.
The study measures technology out-licensing as the count of out-licensing deals. This captures licensing activity, but it does not directly measure the economic value, strategic importance, royalty structure, or technological content of each license.
The study does not systematically link each out-licensed technology to a specific prior acquisition. The analysis shows that acquisitions predict subsequent out-licensing at the firm-year level, but it cannot always prove that a specific acquired technology was the one licensed out.
Technology uncertainty is measured using patent backward citations. This is a theoretically grounded proxy, but it may not capture all forms of uncertainty, such as clinical uncertainty, regulatory uncertainty, market uncertainty, or uncertainty around complementary assets.
Financial slack is measured mainly through the equity-to-debt ratio. The authors test alternative slack measures, but slack is still difficult to capture fully because usable financial flexibility depends on managerial priorities, investor expectations, debt covenants, and internal budgeting processes.
The 2SLS approach strengthens causal interpretation, but the study remains observational. Unobserved factors could still shape acquisition and out-licensing decisions despite fixed effects, instruments, and robustness checks.
The time period covers 1985 to 2014. The biopharmaceutical industry has continued to change since then, especially through platform technologies, digital health, AI-enabled discovery, and new financing models.
Future research
Future research could test whether the acquisition-out-licensing relationship holds in other industries, such as software, semiconductors, chemicals, clean technology, automotive, medical devices, and industrial technology.
Researchers could link specific acquired patents, products, or technologies to later out-licensing transactions. This would clarify whether firms license out technologies directly acquired from targets or whether acquisitions trigger broader reconfiguration of the acquirer’s pre-existing R&D portfolio.
Future studies could examine the performance consequences of post-acquisition out-licensing. It would be useful to know when out-licensing improves innovation performance, financial performance, R&D productivity, or strategic flexibility.
Another useful direction would be to study the design of out-licensing contracts after acquisitions. Contract terms such as grant-back clauses, royalties, exclusivity, field-of-use restrictions, and milestone payments may shape whether out-licensing preserves or destroys strategic value.
Researchers could examine how firms build dedicated out-licensing capabilities. Some firms may be better than others at identifying licenseable technologies, protecting strategic assets, and selecting external partners.
Future research could compare out-licensing with other reconfiguration strategies, including divestitures, discontinuations, internal redeployment, alliances, spinouts, and joint ventures.
Researchers could also investigate how financial slack affects the timing of post-acquisition reconfiguration. Firms with slack may delay out-licensing while they evaluate acquired technologies, whereas constrained firms may license earlier.
Finally, future studies could examine how uncertainty changes over time after acquisition. As firms learn more about acquired technologies, they may shift from internal exploration to out-licensing, discontinuation, or commercialization.